Wellington Management Group LLP Has $9.13 Million Stake in Replimune Group, Inc. $REPL

Key Points

• Wellington Management Group LLP reduced its stake in Replimune Group by 14.6%, now holding approximately 1.22% of the company worth around $9.13 million.
• Replimune Group's earnings report showed a loss of ($0.95) EPS, missing estimates, while analysts project a -2.97 EPS for the current year.
• Recent analyst ratings have varied widely, with Piper Sandler lowering its price target to $3.00, while Jefferies set a target at $6.00, reflecting uncertainty about the company's stock performance.

Wellington Management Group LLP reduced its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 14.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 936,360 shares of the company's stock after selling 160,384 shares during the quarter. Wellington Management Group LLP owned about 1.22% of Replimune Group worth $9,130,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Redmile Group LLC boosted its position in shares of Replimune Group by 2.6% during the 4th quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock worth $59,406,000 after purchasing an additional 124,344 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Replimune Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after purchasing an additional 237,185 shares in the last quarter. Tang Capital Management LLC lifted its holdings in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after purchasing an additional 1,500,000 shares in the last quarter. RTW Investments LP lifted its holdings in Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after purchasing an additional 931,223 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in shares of Replimune Group during the 4th quarter valued at about $21,754,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Leerink Partners reaffirmed a "market perform" rating and set a $3.00 price objective (down previously from $21.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $9.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. BMO Capital Markets cut Replimune Group from an "outperform" rating to an "underperform" rating and reduced their price objective for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Jefferies Financial Group lowered their price target on Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, HC Wainwright lowered shares of Replimune Group from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Replimune Group presently has an average rating of "Hold" and a consensus price target of $6.50.

Replimune Group Stock Performance

Shares of REPL stock traded up $0.02 during trading on Friday, reaching $5.40. The company had a trading volume of 2,254,879 shares, compared to its average volume of 4,925,989. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94. The firm's 50 day simple moving average is $7.38 and its two-hundred day simple moving average is $9.00. The company has a market capitalization of $421.52 million, a PE ratio of -1.67 and a beta of 0.67. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the sale, the chief financial officer directly owned 134,368 shares in the company, valued at approximately $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.20% of the company's stock.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.